XML 72 R23.htm IDEA: XBRL DOCUMENT v3.19.3
Segment Information (Tables)
9 Months Ended
Sep. 30, 2019
Segment Information [Abstract]  
Segment Information

The following tables show our segment revenue and income (loss) from operations for the three and nine months ended September 30, 2019 and 2018 (in thousands), respectively.


Three Months Ended September 30, 2019
 
Ionis Core
   
Akcea Therapeutics
   
Elimination of
Intercompany Activity
   
Total
 
Revenue:
                       
Commercial revenue:
                       
SPINRAZA royalties
 
$
81,672
   
$
   
$
   
$
81,672
 
Product sales, net
   
     
11,945
     
     
11,945
 
Licensing and other royalty revenue
   
1,946
     
136
     
     
2,082
 
Total commercial revenue
   
83,618
     
12,081
     
     
95,699
 
R&D revenue under collaborative agreements
   
69,165
     
8,543
     
(5,515
)
   
72,193
 
Total segment revenue
 
$
152,783
   
$
20,624
   
$
(5,515
)
 
$
167,892
 
Total operating expenses
 
$
119,147
   
$
53,215
   
$
(6,993
)
 
$
165,369
 
Income (loss) from operations
 
$
33,636
   
$
(32,591
)
 
$
1,478
   
$
2,523
 

Three Months Ended September 30, 2018
 
Ionis Core
   
Akcea Therapeutics
   
Elimination of
Intercompany Activity
   
Total
 
Revenue:
                       
Commercial revenue:
                       
SPINRAZA royalties
 
$
70,010
   
$
   
$
   
$
70,010
 
Licensing and other royalty revenue
   
7,946
     
12,000
     
(7,200
)
   
12,746
 
Total commercial revenue
   
77,956
     
12,000
     
(7,200
)
   
82,756
 
R&D revenue under collaborative agreements
   
100,105
     
7,241
     
(44,707
)
   
62,639
 
Total segment revenue
 
$
178,061
   
$
19,241
   
$
(51,907
)
 
$
145,395
 
Total operating expenses
 
$
87,664
   
$
84,249
   
$
(7,946
)
 
$
163,967
 
Income (loss) from operations
 
$
90,397
   
$
(65,008
)
 
$
(43,961
)
 
$
(18,572
)

Nine Months Ended September 30, 2019
 
Ionis Core
   
Akcea Therapeutics
   
Elimination of
Intercompany Activity
   
Total
 
Revenue:
                       
Commercial revenue:
                       
SPINRAZA royalties
 
$
211,884
   
$
   
$
   
$
211,884
 
Product sales, net
   
     
28,563
     
     
28,563
 
Licensing and other royalty revenue
   
8,466
     
6,172
     
(3,000
)
   
11,638
 
Total commercial revenue
   
220,350
     
34,735
     
(3,000
)
   
252,085
 
R&D revenue under collaborative agreements
   
294,512
     
176,328
     
(94,007
)
   
376,833
 
Total segment revenue
 
$
514,862
   
$
211,063
   
$
(97,007
)
 
$
628,918
 
Total operating expenses
 
$
355,437
   
$
256,152
   
$
(87,900
)
 
$
523,689
 
Income (loss) from operations
 
$
159,425
   
$
(45,089
)
 
$
(9,107
)
 
$
105,229
 

Nine Months Ended September 30, 2018
 
Ionis Core
   
Akcea Therapeutics
   
Elimination of
Intercompany Activity
   
Total
 
Revenue:
                       
Commercial revenue:
                       
SPINRAZA royalties
 
$
167,743
   
$
   
$
   
$
167,743
 
Licensing and other royalty revenue
   
9,432
     
12,000
     
(7,200
)
   
14,232
 
Total commercial revenue
   
177,175
     
12,000
     
(7,200
)
   
181,975
 
R&D revenue under collaborative agreements
   
232,850
     
42,670
     
(49,936
)
   
225,584
 
Total segment revenue
 
$
410,025
   
$
54,670
   
$
(57,136
)
 
$
407,559
 
Total operating expenses
 
$
279,084
   
$
213,428
   
$
(12,796
)
 
$
479,716
 
Income (loss) from operations
 
$
130,941
   
$
(158,758
)
 
$
(44,340
)
 
$
(72,157
)


The following table shows our total assets by segment at September 30, 2019 and December 31, 2018 (in thousands), respectively.


Total Assets
 
Ionis Core
   
Akcea Therapeutics
   
Elimination of
Intercompany Activity
   
Total
 
September 30, 2019
 
$
3,233,175
   
$
383,167
   
$
(721,353
)
 
$
2,894,989
 
December 31, 2018
 
$
2,975,491
   
$
365,261
   
$
(672,968
)
 
$
2,667,784